. 2015 Nov 20;15:19. doi: 10.1186/s40644-015-0055-z

Table 2.

Principal characteristics of the 15 studies included in the meta-analysis

Study	Publication year	Number of patients	Study design	PET/CT timing	Type of treatment	End points^a	Methodology score (%)
de Geus-Oei L F et al.	2006	152	Retrospective	Pretreatment	Resection or Chemotherapy	OS	83.33 %
Small RM et al. [21]	2009	54	retrospective	Pretreatment and posttreatment	Chemotherapy	OS EFS(PFS)	50.00 %
Hendlisz A et al.	2011	41	Prospective	Pretreatment and posttreatment	Chemotherapy	OS EFS(PFS)	70.83 %
Muralidharan V et al.	2012	30	retrospective	Pretreatment	Resection	OS EFS(RFS)	75.00 %
De Bruyne S et al. [22]	2012	19	Retrospective	Pretreatment and posttreatment	Chemotherapy and bevacizumab	EFS(PFS)	75.00 %
Lastoria S et al.	2013	33	Retrospective	Pretreatment and posttreatment	Chemotherapy and Bevacizumab	EFS(PFS) OS	66.67 %
Mertens J et al. [23]	2013	18	Prospective	Pretreatment and posttreatment	Chemotherapy and Bevacizumab	OS	75.00 %
Zerizer I et al.	2013	25	Retrospective	Pretreatment and posttreatment	⁹⁰Y radioembolization	EFS(PFS)	70.83 %
Fendler W P et al.	2013	80	Retrospective	Pretreatment and posttreatment	⁹⁰Y radioembolization	OS	62.50 %
Jones C et al.	2014	79	retrospective	Pretreatment	Resection	OS	54.17 %
Lee HS et al. [24]	2014	120	retrospectively	Pretreatment	Resection	OS EFS(RFS)	83.33 %
Lau LF et al.	2014	37	retrospective	Pretreatment and posttreatment	Chemotherapy	OS EFS(RFS)	58.33 %
Riedl CC et al. [25]	2007	90	retrospective	Pretreatment	Resection	OS	54.17 %
Correa-Gallego C et al.	2015	38	Prospective	Pretreatment and posttreatment	Chemotherapy and bevacizumab	OS EFS(PFS)	83.33 %
Sabet A et al.	2015	51	retrospective	Pretreatment and posttreatment	⁹⁰Y radioembolization	OS	70.83 %

^a"end points": time elapsed between treatment initiation and disease progression or death